These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26404928)

  • 1. Alternate approaches for pediatric type 1 diabetes drug development and potential regulatory approval: a perspective.
    Turner JR; Close KL; Fleming GA; Wherrett DK; DiMeglio LA
    Diabetes Care; 2015 Oct; 38(10):1986-91. PubMed ID: 26404928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 3. Incentivizing Orphan Product Development: United States Food and Drug Administration Orphan Incentive Programs.
    Le TT
    Adv Exp Med Biol; 2017; 1031():183-196. PubMed ID: 29214572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Medicine, Diabetes, and the U.S. Food and Drug Administration.
    Meyer RJ
    Diabetes Care; 2016 Nov; 39(11):1874-1878. PubMed ID: 27926889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric drug development programs for type 2 diabetes: A review.
    Christensen ML; Franklin BE; Momper JD; Reed MD
    J Clin Pharmacol; 2015 Jul; 55(7):731-8. PubMed ID: 25781151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encouraging research and development of pediatric medical devices through legislative and regulatory action: the Pediatric Medical Device Safety and Improvement Act of 2007 in context.
    Bleicher EW
    Food Drug Law J; 2009; 64(3):531-64. PubMed ID: 19999642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 8. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C; Xu K; Freeman SN; Bonnel RA; Joseph F; Phillips MI; Imoisili MA
    Pediatrics; 2012 Mar; 129(3):516-21. PubMed ID: 22371464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes.
    Farrell R; Bethin K; Klingensmith G; Tamborlane WV; Gubitosi-Klug R
    Pediatr Diabetes; 2017 Nov; 18(7):574-578. PubMed ID: 27807915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Pediatric Research Equity Act Moves Into Adolescence.
    Bourgeois FT; Hwang TJ
    JAMA; 2017 Jan; 317(3):259-260. PubMed ID: 28114560
    [No Abstract]   [Full Text] [Related]  

  • 11. Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer.
    Vassal G; Kearns P; Blanc P; Scobie N; Heenen D; Pearson A
    Eur J Cancer; 2017 Oct; 84():149-158. PubMed ID: 28818704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel diabetes drugs to face higher hurdles?
    Opar A
    Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340
    [No Abstract]   [Full Text] [Related]  

  • 13. A clinical pharmacology-regulatory perspective on the approval of drugs for rare diseases.
    Bashaw ED
    Clin Pharmacol Ther; 2016 Oct; 100(4):327-9. PubMed ID: 27417549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development.
    Mittermayer F; Caveney E; De Oliveira C; Fleming GA; Gourgiotis L; Puri M; Tai LJ; Turner JR
    Curr Diabetes Rev; 2017; 13(3):300-314. PubMed ID: 27071617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory issues in the approval of new drugs for diabetes mellitus, dyslipidemia, and the metabolic syndrome.
    Isaacsohn JL; Troendle AJ; Orloff DG
    Am J Cardiol; 2004 Jun; 93(11A):49C-52C. PubMed ID: 15178516
    [No Abstract]   [Full Text] [Related]  

  • 18. The Regulatory Pathway for Antifungal Drugs: A US Perspective.
    Tillotson J; Tillotson GS
    Clin Infect Dis; 2015 Dec; 61 Suppl 6():S678-83. PubMed ID: 26567287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botanicals as "new" drugs: US development.
    Hoffman FA
    Epilepsy Behav; 2015 Nov; 52(Pt B):338-43. PubMed ID: 26319115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.